Revolutionary arthritis treatment nominated for KCA Best Commercial Deal 2014

September 1, 2014

Dendright’s efforts to translate research in the field of autoimmune disease has won a nomination in the Knowledge Commercialisation Australasia (KCA) Research Commercialisation Awards.  

The commercial deal, which was struck between Janssen Biotech, Inc. and Dendright, a UniQuest start-up company commercialising the research of UQ’s Diamantina Institute’s Professor Ranjeny Thomas, has been named a finalist in the Best Commercial Deal category as well as being nominated as an entrant for the People’s Choice Awards.

The deal is concerned with development of a highly novel treatment for rheumatoid arthritis (RA).

RA is caused by immune system dysfunction and affects millions of people worldwide, destroying joints and causing cardiovascular complications that can reduce life span by a decade.

The proposed treatment targets the underlying cause of RA rather than simply treating the inflammatory symptoms.

If successful, the research could also influence the way that other autoimmune diseases such as type 1 diabetes are treated, improving the health of millions.

The awards serve to celebrate deals which have been transacted in the past year which showcase and recognise the powerful relationships and partnerships transforming Australia’s cutting edge research into products and services. Entrants will be judged on a variety of criteria including the use of innovative deal structures, the potential long-term social and economic impact of the transaction and the flow-through of benefits to stakeholders.

The winner of both categories will be announced at the KCA annual conference dinner in Brisbane on September 18th 2014.

Vote here for the People’s Choice Awards which closes 5pm Brisbane time 18th September 2014.

Media Enquiries: 

Helen Roberts, CEO, 0419 657504, helen@dendright.com.au

Share This